业绩承压 狂犬病疫苗龙头康华生物总裁辞职

Core Viewpoint - The resignation of the president of Kanghua Biological, Wu Hongbo, is speculated to be linked to the company's significant decline in performance, with a projected net profit drop for 2025 compared to the previous year [2][3]. Company Performance - Kanghua Biological's latest performance forecast indicates a net profit attributable to shareholders for 2025 is expected to be between 191 million and 233 million yuan, a substantial decrease from 399 million yuan in the same period last year [2]. - The net profit after deducting non-recurring gains and losses is projected to be between 208 million and 230 million yuan, representing a year-on-year decline of 49.73% to 54.54% [2]. Reasons for Performance Decline - The decline in performance is attributed to two main factors: a decrease in vaccine sales revenue by approximately 11% due to industry policy adjustments and market competition, and the absence of overseas licensing income for the year 2025, which previously contributed significant profit [2][3]. - The company's product structure is overly reliant on a single product, the freeze-dried human rabies vaccine, which poses a risk as competition intensifies from other companies with similar products expected to be approved this year [3]. Control Change and Profit Guarantee - In July 2025, Kanghua Biological underwent a change in control, with the previous controlling shareholder transferring 21.91% of shares to Shanghai Wankexin Biological, resulting in a new controlling entity without an actual controller [3]. - A "profit guarantee agreement" was signed, stipulating that the company must achieve a total net profit of no less than 728 million yuan from 2025 to 2026, or compensate the acquirer for any shortfall [3][4]. Future Prospects - To address the dual challenges of performance guarantees and product singularity, Kanghua Biological is focusing on new product development, including the initiation of clinical trials for a new six-valent norovirus vaccine [4].